Pfizer’s Oncology Research Unit is interested in partnering with groups that have electronic databases of genetic alterations including single nucleotide substitutions, insertions, deletions, copy number changes and chromosomal rearrangements based on Next-Generation Sequencing (NGS) profiling of tumors from cancer patients.
These genetic profiles may be derived from targeted sequencing of known cancer genes or whole exome/genome sequencing. Pfizer is interested in data on many cancer types that have a higher prevalence in Asian populations including gastric, liver, esophageal and lung cancers.
Successful databases require the following specifications:
- Database should be organized by international standards (English, HUGO gene symbols etc.) with the data regularly curated, updated and available to Pfizer through transfer of complete data sets
- Informed consent should be in place to allow broad research use of tissue specimens and derived genetic data
- Tumor molecular profiles need to have annotations on tumor diagnosis, histology and whenever applicable, drug response and survival data
- It is preferable that tumor molecular profiles are linked to tissue specimens stored in a biobank in conditions amenable for creating cell cultures or xenograft. Tissues should be available for RNA profiling, IHC or proteomics analysis